- The CDC reported more than 670,000 annual deaths in the United States with high blood pressure as a primary or contributing cause
- Lexaria’s patented DehydraTECH(TM) technology has been shown, through HYPER-H21-4 study, to decrease high blood pressure in subjects through DehydraTECH-CBD-enabled dosing
- The global antihypertension drug market was valued at over $22.5 billion in revenue in 2018 and is expected to grow at a CAGR of 3.1%, resulting in a market of over $28.7 billion by 2026
In the United States, uncontrolled high blood pressure is common among adults – with only one in four having the condition under control. According to the Centers for Disease Control and Prevention (“CDC”), in 2020, more than 670,000 deaths in the United States had high blood pressure as a primary or contributing cause (https://cnw.fm/oH9ZC). Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced that its human clinical study HYPER-H21-4 may be the world’s first study to evidence a sustained drop in blood pressure in normally active patients following multiple weeks of oral cannabidiol (“CBD”) therapy using the company’s patented DehydraTECH(TM)-enabled CBD capsule formulation.
According to company CEO Chris Bunka, this is an exceptional discovery, given that previous studies by others using other oral CBD formulations have failed to evidence this sustained benefit. Additionally, DehydraTECH also demonstrated excellent safety and tolerability results and no adverse changes in liver enzymes throughout the study (https://cnw.fm/9bluE).
“Indeed, of the handful of minor, non-serious adverse events reported, there were nearly as many reported by those patients receiving placebo as those who received DehydraTECH-CBD,” Bunka added. “Consistent with Lexaria’s often-mentioned de-risking strategy, this exceptional safety profile should prove beneficial as we prepare for our planned upcoming Phase Ib Investigational New Drug clinical study to be registered with the U.S. Food and Drug Administration.”
The primary safety and efficacy objectives of the HYPER-H21-4 study were achieved, with a significant reduction in blood pressure achieved in 2.5 weeks and over the course of the five weeks of dosing. During the trial, zero serious adverse events were reported. No adverse changes were observed in liver enzymes, which is an important clinical safety biomarker of oral CBD therapy. The study notes that a significant blood pressure decrease was achieved using relatively low doses of DehydraTECH-CBD, a key indicator of the well-established drug delivery efficiencies of the company’s technology – with superior power evidenced through its unique formulation to reduce blood pressure over other oral CBD formulation (https://cnw.fm/NVoDQ).
The positive findings emphasize Lexaria’s unique position to address the unmet needs of the growing antihypertension drug market. The industry was responsible for $22,557 million in revenue in 2018 and is expected to grow at a CAGR of 3.1%, resulting in $28,797 million by 2026 (https://cnw.fm/jISXH).
Lexaria’s DehydraTECH technology was designed for formulating and delivering lipophilic drugs and active ingredients. It increases effectiveness and improves how active pharmaceutical ingredients (“APIs”) enter the bloodstream. The benefits of Lexaria’s DehydraTECH technology include the following:
- Speeds up the delivery so that effects are felt in minutes
- Increased bioavailability
- Increased brain absorption
- Improves drug potency
- Reduces drug administration costs so that lower doses are necessary
- Masks unwanted taste, eliminating and reducing the need for sweeteners
Since 2016, Lexaria has demonstrated, through its DehydraTECH technology, the ability to increase bio-absorption by up to five to ten times. It has reduced the onset time from one to two hours to just minutes. It will be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, nicotine and more.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
